Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Since the discovery of MHC molecules, it has taken 40 years to arrive at a coherent picture
of how MHC class I and MHC class II molecules really work. This is a story of the proteases …

The broad application of precision cancer immunotherapies is limited by the number of
validated neoepitopes that are common among patients or tumor types. To expand the …

A number of machine learning-based predictors have been developed for identifying
immunogenic T-cell epitopes based on major histocompatibility complex (MHC) class I and II …

Summary HLA class I (HLA-I) glycoproteins drive immune responses by presenting antigens
to cognate CD8+ T cells. This process is often hijacked by tumors and pathogens for …

Introduction: In modern vaccinology and immunotherapy, recombinant proteins more and
more replace whole organisms to induce protective or curative immune responses …

The processing of MHC class I antigenic precursor peptides by the endoplasmic reticulum
aminopeptidase 1 (ERAP1) and ERAP2 is an important event in the cell biology of antigen …

Neoantigen cancer vaccines have been envisioned as one of the most promising means for
cancer therapies. However, identifying neoantigens for tumor types with low tumor mutation …

Deeper understanding of T-cell-mediated adaptive immune responses is important for the
design of cancer immunotherapies and antiviral vaccines against pandemic outbreaks. T …

Abstract MHC class I (MHC-I) molecules present a blueprint of the intracellular proteome to T
cells allowing them to control infection or malignant transformation. As a response …